SYNLAB BONDCO PLC Overview
Company Headquarters: London, UK
Founded: 2015
Workforce: ~22,000
Company Working: SYNLAB Bondco PLC (SYNLAB) was incorporated on 9 June 2015 and acquired the Labco Group on 7 August 2015 and the Synlab Group on 1 October 2015. The main business of the SYNLAB Bondco PLC is the supply of medical diagnostic services, primarily relating to clinical diagnostics testing, and screening services. It is also active in analytics & services business covering notably environmental and food testing. This company focuses on medical supplies, trade, clinical trials, and offers consulting services. Its customers include doctors, patients, clinics, university hospitals, retirement and nursing homes, veterinary practices, business enterprises, communities and authorities, and pharmaceutical companies.
SYNLAB particularly focuses on the implementation of innovative laboratory medicine methods and networking specialist diagnostic competences (SYNLAB Centers of Excellence). SYNLAB maintains its strategic business units in individual countries for veterinary medicine and environmental analysis. This service portfolio is rounded off by expert medical imaging centers in certain countries. The group works closely with research institutions and universities and maintains an educational institution named the SYNLAB Academy.
The company is present in more than 37 countries globally. It has a workforce of around 22,000 employees spread across the globe. It performs approximately 450 million test results per annum. It benefits from a network of over 475 laboratories across 37 countries worldwide, including the core markets of Germany, France, Switzerland, Italy, and Spain. It completed 33 acquisitions in 2017 and 21 acquisitions in 2018.
Strategy
SYNLAB Bondco PLC intends to continue to grow its business by expanding its services offering. It will also focus on leveraging the business’s scale, capabilities, and supplier relationships to drive operating efficiencies by streamlining its lab operations and administrative functions. The group expects to pursue growth opportunities through selective acquisitions in the markets in which it already operates.
